



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

31st March 2021

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

**Sub: Approval of Sale of Company's Manufacturing Facility located at Vemgal,
Karnataka**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("LODR"), we wish to inform you:

- 1) The Board of Directors of GlaxoSmithKline Pharmaceuticals Limited (the "**Company**") at its meeting held yesterday approved the sale of the Company's business undertaking i.e., manufacturing facility together with the land, plant and machinery, assets, software and equipment located at Vemgal, Karnataka to Hetero Labs Limited, a company incorporated under the laws of India with CIN: U24110TG1989PLC009723 and having its registered office at 7-2-A2, Hetero Corporate Industrial Estate, Sanath Nagar, Hyderabad 500018, Telangana, India ("**Transaction**").
- 2) The Transaction is subject to receipt of all statutory approvals from the concerned authorities & members of the Company and signing of the definitive documents between the Company and Hetero Labs Limited in this regard.

The relevant disclosure in terms of SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9 September 2015 is enclosed as **Annexure-A**.

Kindly take submission on record.

Yours faithfully,
For: **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President - Administration, Real Estate
& Company Secretary

Annexure - A

S. No.	Particulars	Details
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year.	Nil
2.	Date on which the agreement for sale has been entered into.	The asset transfer agreement (the "ATA") is expected to be entered into within a period of [5] business days. The asset sale is conditional upon satisfactory completion of the respective conditions, precedent by the parties (including obtaining members' approval and applicable statutory approvals).
3.	The expected date of completion of sale/disposal.	Subject to satisfactory completion of the respective conditions, precedent by the parties and in accordance with the other provisions of the ATA, the transaction is expected to be completed by 30 September 2021.
4.	Consideration received from such sale/disposal.	INR 180 crores.
5.	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof.	The buyer of the manufacturing facility is Hetero Labs Limited. The buyer does not belong to the promoter / promoter group / group companies.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at arms' length.	No
7.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable

gled/kor